Donor Cell Leukemia: A Review

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 6, 2011, Pages 771-789

  Wiseman, Daniel H ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acute leukemia; Donor; Hematopoietic stem cell transplantation; Leukemogenesis

Indexed keywords

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; DONOR SELECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMOGENESIS; RELAPSE; REVIEW; UMBILICAL CORD BLOOD;

ACUTE DISEASE; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; CHIMERISM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECURRENCE; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79956018813     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.010     Document Type: Review

References (162)

1. Myron Kauffman H., McBride M.A., Cherikh W.S., Spain P.C., Marks W.H., Roza A.M. Transplant tumor registry: donor related malignancies. Transplantation 2002, 74:358-362.
2. Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994, 12:1710-1717.
3. Giralt S.A., Champlin R.E. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994, 84:3603-3612.
4. Fialkow P.J., Thomas E.D., Bryant J.I., Neiman P.E. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1971, 1:251-255.
5. Boyd C.N., Ramberg R.C., Thomas E.D. The incidence of recurrence of leukemia in donor cells after allogeneic bone marrow transplantation. Leuk Res 1982, 6:833-837.
6. Hertenstein B., Hambach L., Bacigalupo A., et al. Development of leukemia in donor cells after allogeneic stem cell transplantation-a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2005, 90:969-975.
7. Sala-Torra O., Hanna C., Loken M.R., et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:511-517.
8. Ruiz-Argüelles G.J., Ruiz-Delgado G.J., Garces-Eisele J., Ruiz-Arguelles A., Perez-Romano B., Reyes-Nuñez V. Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: a single institution experience. Leuk Lymphoma 2006, 47:1952-1955.
9. Thomas E.D., Bryant J.I., Buckner C.D., et al. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1972, 1:1310-1313.
10. Goh K., Klemperer M.R. In vivo leukemic transformation: cytogenetic evidence of in vivo leukemic transformation of engrafted marrow cells. Am J Hematol 1977, 2:283-290.
11. Elfenbein G.J., Brogaonkar D.S., Bias W.B., et al. Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cells. Blood 1978, 52:627-636.
12. Newburger P.E., Latt S.A., Pesando J.M., et al. Leukemia relapse in donor cells after allogeneic bone-marrow transplantation. N Engl J Med 1981, 304:712-714.
13. Marmont A., Frassoni F., Bacigalupo A., et al. Recurrence of Ph'-positive leukemia in donor cells after marrow transplantation for chronic granulocytic leukemia. N Engl J Med 1984, 310:903-906.
14. McCann S.R., Lawler M., Humphries P., et al. Recurrence of Philadelphia chromosome-positive leukemia in donor cells after marrow transplantation for chronic granulocytic leukemia: confirmation by microsatellite studies. Blood 1992, 79:2803-2805.
15. Smith J.L., Heerema N.A., Provisor A.J. Leukaemic transformation of engrafted bone marrow cells. Br J Haematol 1985, 60:415-422.
16. Witherspoon R.P., Schubach W., Neiman P., Martin P., Thomas E.D. Donor cell leukemia developing six years after marrow grafting for acute leukemia. Blood 1985, 65:1172-1174.
17. Zaccaria A., Rosti G., Testoni N., et al. Chromosome studies in patients with acute nonlymphocytic or acute lymphocytic leukemia submitted to bone marrow transplantation-results of a European cooperative study. Cancer Genet Cytogenet 1987, 26:51-58.
18. Palka G., Calabrese G., Di Girolamo G., et al. Cytogenetic survey of 31 patients treated with bone marrow transplantation for acute nonlymphocytic and acute lymphoblastic leukemias. Cancer Genet Cytogenet 1991, 51:223-233.
19. Schmitz N., Johannson W., Schmidt G., von der Helm K., Löffler H. Recurrence of acute lymphoblastic leukemia in donor cells after allogeneic marrow transplantation associated with a deletion of the long arm of chromosome 6. Blood 1987, 70:1099-1104.
20. Feig S.A., Dreazen O., Simon M., Wiley F., Schreck R., Gale R.P. B cell acute lymphoblastic leukemia (ALL) in donor cells following bone marrow transplantation for T cell ALL. Bone Marrow Transplant 1988, 3:331-337.
21. Browne P.V., Lawler M., Humphries P., McCann S.R. Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia. N Engl J Med 1991, 325:710-713.
22. Cullis J.O., Marks D.I., Schwarer A.P., et al. Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases. Br J Haematol 1992, 81:378-382.
23. Cransac M., Boiron J.M., Merel P., et al. Burkitt-type acute lymphoblastic leukemia in donor cells after allogeneic bone marrow transplantation for acute nonlymphoblastic leukemia. Transplantation 1993, 56:120-123.
24. Mouratidou M., Sotiropoulos D., Deremitzaki K., et al. Recurrence of acute leukemia in donor cells after bone marrow transplantation: documentation by in situ DNA hybridization. Bone Marrow Transplant 1993, 12:77-80.
25. Katz F., Reeves B.R., Alexander S., Kearney L., Chessells J. Leukaemia arising in donor cells following allogeneic bone marrow transplantation for beta thalassaemia demonstrated by immunological, DNA and molecular cytogenetic analysis. Br J Haematol 1993, 85:326-331.
26. Lowsky R., Fyles G., Minden M., et al. Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. Br J Haematol 1996, 93:163-165.
27. Shekhter-Levin S., Bloom E.J., Swerdlow S.H., Sherer M.E., Wald N., Gollin S.M. Acquired monosomy 7 in donor cells in a patient treated for acute lymphoblastic leukemia with bone marrow transplantation. Cancer Genet Cytogenet 1997, 95:190-197.
28. Cooley L.D., Sears D.A., Udden M.M., Harrison W.R., Baker K.R. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 2000, 63:46-53.
29. Saito Y., Uzuka Y., Sakai N., Suzuki S., Toyota T. A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Bone Marrow Transplant 2000, 25:1209-1211.
30. Hambach L., Eder M., Dammann E., et al. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 2001, 28:705-707.
31. Lawler M., Locasciulli A., Longoni D., Schiro R., McCann S.R. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant 2002, 29:453-456.
32. Brunstein C.G., Hirsch B.A., Hammerschmidt D., McGlennen R.C., Nguyen P.L., Verfaillie C.M. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2002, 29:999-1003.
33. Gopcsa L., Barta A., Banyai A., et al. Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2002, 29:449-452.
34. Au W.Y., Chan E.C., Siu L.L.P., et al. Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma. Br J Haematol 2002, 119:777-780.
35. Haltrich I., Müller J., Szabó J., et al. Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. Cancer Genet Cytogenet 2003, 142:124-128.
36. Komeno Y., Kanda Y., Kandabashi K., et al. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin. Am J Hematol 2003, 72:220-222.
37. Bielorai B., Deeg H.J., Weintraub M., et al. B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation. Bone Marrow Transplant 2003, 31:931-934.
38. Daly A.S., Kamel-Reid S., Lipton J.H., et al. Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leuk Res 2004, 28:1107-1111.
39. Komrokji R., Ifthikharuddin J.J., Felgar R.E., et al. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review. Am J Hematol 2004, 76:389-394.
40. Lang Z., Dinndorf P., Ladisch S., Bayever E., Reaman G. Chromosomal transformation in donor cells following allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 33:1253-1256.
41. Orciuolo E., Azzarà A., Bandini G., et al. Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. Bone Marrow Transplant 2004, 33:859-861.
42. Athanasiadou A., Stamatopoulos K., Sakellari I., et al. Development of BCR-ABL positive acute lymphoblastic leukemia in donor cells after allogeneic hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2004, 34:189-191.
43. Boulton-Jones R., Parker A., Hepburn M., Bowen D.T. Secondary myelodysplasia of donor cell origin following nonmyeloablative sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36:471-472.
44. Matsunaga T., Murase K., Yoshida M., et al. Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol 2005, 79:294-298.
45. Fraser C.J., Hirsch B.A., Dayton V., et al. First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood 2005, 106:4377-4380.
46. Kraut L., Trebeljahr G., Thiele B., Fauser A.A. Donor cell-derived myelodysplastic syndrome in a patient 7 years after unrelated allogeneic HLA-mismatched transplantation for Ph+ chronic myeloid leukemia. Bone Marrow Transplant 2005, 36:737.
47. Beck C., Humpe A., Harder S., Schmid M., Horst H.A. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient. Ann Hematol 2005, 84:616-618.
48. Reichard K.K., Zhang Q.-Y., Sanchez L., Hozier J., Viswanatha D., Foucar K. Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: case report and review of the literature. Am J Hematol 2006, 81:178-185.
49. Pieroni F., Oliveira F.M., Panepucci R.A., Voltarelli J.C., Simões B.P., Falcão R.P. Development of donor cell derived acute myeloid leukemia after stem cell transplantation for chronic myeloid leukemia. Bone Marrow Transplant 2006, 37:801-802.
50. Ataergin S., Arpaci F., Cetin T., et al. Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia. Am J Hematol 2006, 81:370-373.
51. Havelange V., Antoine-Poirel H., Saussoy P., Van Den Neste E., Ferrant A. Donor cell leukemia developing after hematopoietic stem cell transplantation for multiple myeloma. Acta Clin Belg 2006, 61:82-86.
52. Hashino S., Fujisawa F., Kondo T., et al. Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. Int J Hematol 2006, 84:363-366.
53. Ando T., Yujiri T., Mitani N., et al. Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation. Leukemia 2006, 20:744-745.
54. Cetin Z., Tezcan G., Karauzum S.B., et al. Donor cell-derived acute myeloblastic leukemia after allogeneic peripheral blood hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 2006, 28:763-767.
55. Stevens J.M., Syndercombe-Court D., Oakervee H.E., et al. Development of original donor cell leukemia after successful engraftment from a second donor. Blood 2007, 110:4621-4622.
56. Jacobs J.F.M., Brons P.P., Simons A., van der Reijden B.A., Hoogerbrugge P.M. Therapy-related, donor-derived AML responding to a second allogeneic BMT. Bone Marrow Transplant 2007, 40:499-500.
57. Hamaki T., Kajiwara K., Kami M., et al. Donor cell-derived acute monoblastic leukemia involving MLL gene translocation in an adult patient who received umbilical cord blood transplantation. Bone Marrow Transplant 2008, 41:91-92.
58. Socié G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999, 341:14-21.
59. Benesch M., Deeg H.J. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 2003, 78:981-990.
60. Killmann S.A. Acute leukemia: the kinetics of leukaemic blast cells in man. An analytical review. Ser Haematol 1968, 2:38-102.
61. Keinänen M., Knuutila S., Bloomfield C.D., Elonen E., de la Chapelle A. Bone marrow cytogenetics: the lineage of dividing cells changes during the first few hours in culture. Leukemia 1987, 1:32-37.
62. Buño I., Nava P., Simón A., et al. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 2005, 90:1373-1379.
63. Riske C.B., Morgan R., Ondreyco S., Sandberg A.A. X and Y chromosome loss as sole abnormality in acute non-lymphocytic leukemia (ANLL). Cancer Genet Cytogenet 1994, 72:44-47.
64. Herens C., Brasseur E., Jamar M., Vierset L., Schoenen I., Koulischer L. Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukaemia and preleukaemia. Clin Lab Haematol 1999, 21:17-20.
65. Wiktor A., Rybicki B.A., Piao Z.S., et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000, 27:11-16.
66. Loss of the Y chromosome from normal and neoplastic bone marrows. United Kingdom Cancer Cytogenetics Group (UKCCG). Genes Chromosomes Cancer 1992, 5:83-88.
67. Anastasi J., Thangavelu M., Vardiman J.W., et al. Interphase cytogenetic analysis detects minimal residual disease in a case of acute lymphoblastic leukemia and resolves the question of origin of relapse after allogeneic bone marrow transplantation. Blood 1991, 77:1087-1091.
68. Perla G., Bodenizza C., Falcone A., et al. Misleading cytogenetic evidence of relapse in donor cells after allogeneic bone marrow transplantation corrected by fluorescent in situ hybridization. Haematologica 1995, 80:292-293.
69. Yam P.Y., Petz L.D., Knowlton R.G., et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation 1987, 43:399-407.
70. Minden M.D., Messner H.A., Belch A. Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment length polymorphism. J Clin Invest 1985, 75:91-93.
71. de Weger R.A., Tilanus M.G., Scheidel K.C., van den Tweel J.G., Verdonck L.F. Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats. Br J Haematol 2000, 110:647-653.
72. Schichman S.A., Suess P., Vertino A.M., Gray P.S. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant 2002, 29:243-248.
73. Stein J., Zimmerman P.A., Kochera M., et al. Origin of leukemic relapse after bone marrow transplantation: comparison of cytogenetic and molecular analyses. Blood 1989, 73:2033-2040.
74. Schichman S.A., Lin P., Gilbrech L.J., Gray P.S., Wilson C.S., Sawyer J.R. Bone marrow transplant engraftment analysis with loss of an informative allele. J Mol Diagn 2002, 4:230-232.
75. Zhou M., Sheldon S., Akel N., Killeen A.A. Chromosomal aneuploidy in leukemic blast crisis: a potential source of error in interpretation of bone marrow engraftment analysis by VNTR amplification. Mol Diagn 1999, 4:153-157.
76. Spinelli O., Giussani U., Borleri G., et al. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. Haematologica 2000, 85:1153-1157.
77. Koldehoff M., Steckel N.K., Hlinka M., Beelen D.W., Elmaagacli A.H. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol 2006, 81:735-746.
78. Jiménez-Velasco A., Barrios M., Román-Gómez J., et al. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 2005, 19:336-343.
79. Thiede C. Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers. Am J Pharmacogenomics 2004, 4:177-187.
80. Niederwieser D.W., Appelbaum F.R., Gastl G., et al. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 1990, 322:1794-1796.
81. Baron F., Dresse M.-F., Beguin Y. Transmission of chronic myeloid leukemia through peripheral-blood stem-cell transplantation. N Engl J Med 2003, 349:913-914.
82. Berg K.D., Brinster N.K., Huhn K.M., et al. Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. N Engl J Med 2001, 345:1458-1463.
83. Mielcarek M., Bryant E., Loken M., Zaucha J.M., Torok-Storb B., Storb R. Long-term engraftment and clonal dominance of donor-derived del(20q) hematopoietic cells after allogeneic stem cell transplantation. Blood 2006, 107:1732-1733.
84. Niederwieser D., Gentilini C., Hegenbart U., et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors?. Bone Marrow Transplant 2004, 34:657-665.
85. Kiss T.L., Chang H., Daly A., et al. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals. Bone Marrow Transplant 2004, 33:855-858.
86. Owen C., Barnett M., Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-a review. Br J Haematol 2008, 140:123-132.
87. Birch J.M., Alston R.D., McNally R.J., et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001, 20:4621-4628.
88. German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997, 93:100-106.
89. Kutler D.I., Singh B., Satagopan J., et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003, 101:1249-1256.
90. Shpilberg O., Modan M., Modan B., Chetrit A., Fuchs Z., Ramot B. Familial aggregation of haematological neoplasms: a controlled study. Br J Haematol 1994, 87:75-80.
91. Biernaux C., Loos M., Sels A., Huez G., Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86:3118-3122.
92. Schmitt C., Balogh B., Grundt A., et al. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and sex distribution, breakpoints, and detection method validity. Leuk Res 2006, 30:745-750.
93. Uckun F.M., Herman-Hatten K., Crotty M.L., et al. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 1998, 92:810-821.
94. Mori H., Colman S.M., Xiao Z., et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 2002, 99:8242-8247.
95. Greaves M.F. Cord blood donor cell leukemia in recipients. Leukemia 2006, 20:1633-1634.
96. Loren A.W., Porter D.L., Stadtmauer E.A., Tsai D.E. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003, 31:145-155.
97. Yasunaga J-i., Matsuoka M. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 2007, 14:133-140.
98. Tamaki H., Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006, 354:1758-1759.
99. Ljungman P., Lawler M., Asjö B., et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol 1994, 88:403-405.
100. Duelli D., Lazebnik Y. Cell fusion: a hidden enemy?. Cancer Cell 2003, 3:445-448.
101. Martin I., Ruysschaert J.M. Common properties of fusion peptides from diverse systems. Biosci Rep 2000, 20:483-500.
102. Duelli D.M., Padilla-Nash H.M., Berman D., Murphy K.M., Ried T., Lazebnik Y. A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr Biol 2007, 17:431-437.
103. Hasegawa W., Pond G.R., Rifkind J.T., et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005, 35:51-55.
104. Kaldor J.M., Day N.E., Clarke E.A., et al. Leukemia following Hodgkin's disease. N Engl J Med 1990, 322:7-13.
105. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L. The incidence of secondary leukemias. Haematologica 1999, 84:937-945.
106. Andersen M.K., Christiansen D.H., Jensen B.A., Ernst P., Hauge G., Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001, 114:539-543.
107. Wakeford R. Radiation in the workplace-a review of studies of the risks of occupational exposure to ionising radiation. J Radiol Prot 2009, 29:A61-A79.
108. Vilenchik M.M., Knudson A.G. Radiation dose-rate effects, endogenous DNA damage, and signaling resonance. Proc Natl Acad Sci U S A 2006, 103:17874-17879.
109. Krishnan A., Bhatia S., Slovak M.L., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95:1588-1593.
110. Metayer C., Curtis R.E., Vose J., et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003, 101:2015-2023.
111. Parsons W.B., Watkins C.H., Pease G.L., Childs D.S. Changes in sternal marrow following roentgen-ray therapy to the spleen in chronic granulocytic leukemia. Cancer 1954, 7:179-189.
112. Hollowell J.G., Littlefield L.G. Chromosome damage induced by plasma of x-rayed patients: an indirect effect of x-ray. Proc Soc Exp Biol Med 1968, 129:240-244.
113. Goyanes-Villaescusa V. Chromosomal abnormalities in lymphocytes of children and baby rabbits born from mothers treated by x-radiation before pregnancy. A transplacentary plasmatic chromosome-damaged factor?. Blut 1971, 22:93-96.
114. Goh K. Total-body irradiation and human chromosomes. IV. Cytogenetic follow-up studies 8 and 10 1/2 years after total-body irradiation. Radiat Res 1975, 62:364-373.
115. Pant G.S., Kamada N. Chromosome aberrations in normal leukocytes induced by the plasma of exposed individuals. Hiroshima J Med Sci 1977, 26:149-154.
116. Emerit I., Levy A., Cernjavski L., et al. Transferable clastogenic activity in plasma from persons exposed as salvage personnel of the Chernobyl reactor. J Cancer Res Clin Oncol 1994, 120:558-561.
117. Little J.B. Genomic instability and bystander effects: a historical perspective. Oncogene 2003, 22:6978-6987.
118. Zhou H., Suzuki M., Randers-Pehrson G., et al. Radiation risk to low fluences of alpha particles may be greater than we thought. Proc Natl Acad Sci U S A 2001, 98:14410-14415.
119. Emerit I., Khan S.H., Esterbauer H. Hydroxynonenal, a component of clastogenic factors?. Free Radic Biol Med 1991, 10:371-377.
120. Auclair C., Gouyette A., Levy A., Emerit I. Clastogenic inosine nucleotide as components of the chromosome breakage factor in scleroderma patients. Arch Biochem Biophys 1990, 278:238-244.
121. Morgan W.F. Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation?. Oncogene 2003, 22:7094-7099.
122. Lehnert B.E., Goodwin E.H., Deshpande A. Extracellular factor(s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res 1997, 57:2164-2171.
123. Azzam E.I., De Toledo S.M., Spitz D.R., Little J.B. Oxidative metabolism modulates signal transduction and micronucleus formation in bystander cells from alpha-particle-irradiated normal human fibroblast cultures. Cancer Res 2002, 62:5436-5442.
124. Sagi-Assif O., Trakhtenbrot L., Douer D., Witz I.P. Preleukemia in long-term plasmacytoma-regressor mice. Int J Cancer 1998, 76:689-693.
125. Flores-Figueroa E., Gutiérrez-Espíndola G., Montesinos J.J., Arana-Trejo R.M., Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002, 26:677-686.
126. Blau O., Hofmann W.-K., Baldus C.D., et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 2007, 35:221-229.
127. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
128. Simmons P.J., Przepiorka D., Thomas E.D., Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987, 328:429-432.
129. Banfi A., Bianchi G., Galotto M., Cancedda R., Quarto R. Bone marrow stromal damage after chemo/radiotherapy: occurrence, consequences and possibilities of treatment. Leuk Lymphoma 2001, 42:863-870.
130. Greenberger J.S., Anderson J., Berry L.A., Epperly M., Cronkite E.P., Boggs S.S. Effects of irradiation of CBA/CA mice on hematopoietic stem cells and stromal cells in long-term bone marrow cultures. Leukemia 1996, 10:514-527.
131. Lorimore S.A., Coates P.J., Scobie G.E., Milne G., Wright E.G. Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?. Oncogene 2001, 20:7085-7095.
132. Hayashi T., Kusunoki Y., Hakoda M., et al. Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors. Int J Radiat Biol 2003, 79:129-136.
133. Yoshida K., Nemoto K., Nishimura M., Seki M. Exacerbating factors of radiation-induced myeloid leukemogenesis. Leuk Res 1993, 17:437-440.
134. Barcellos-Hoff M.H., Park C., Wright E.G. Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer 2005, 5:867-875.
135. Peled A., Lee B.C., Sternberg D., Toledo J., Aracil M., Zipori D. Interactions between leukemia cells and bone marrow stromal cells: stroma-supported growth vs. serum dependence and the roles of TGF-beta and M-CSF. Exp Hematol 1996, 24:728-737.
136. Greenberger J.S., Epperly M.W., Jahroudi N., et al. Role of bone marrow stromal cells in irradiation leukemogenesis. Acta Haematol 1996, 96:1-15.
137. Coates P.J., Rundle J.K., Lorimore S.A., Wright E.G. Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res 2008, 68:450-456.
138. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.
139. Flynn C.M., Kaufman D.S. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood 2007, 109:2688-2692.
140. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004, 22:1136-1151.
141. Mackall C.L., Bare C.V., Granger L.A., Sharrow S.O., Titus J.A., Gress R.E. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996, 156:4609-4616.
142. Rizzo J.D., Curtis R.E., Socié G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
143. Douek D.C., Vescio R.A., Betts M.R., et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000, 355:1875-1881.
144. Storek J., Joseph A., Espino G., et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001, 98:3505-3512.
145. Chklovskaia E., Nowbakht P., Nissen C., Gratwohl A., Bargetzi M., Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 2004, 103:3860-3868.
146. Sevilla J., Querol S., Molines A., et al. Transient donor cell-derived myelodysplastic syndrome with monosomy 7 after unrelated cord blood transplantation. Eur J Haematol 2006, 77:259-263.
147. Mantadakis E., Shannon K.M., Singer D.A., et al. Transient monosomy 7: a case series in children and review of the literature. Cancer 1999, 85:2655-2661.
148. Thornley I., Freedman M.H. Telomeres, X-inactivation ratios, and hematopoietic stem cell transplantation in humans: a review. Stem Cells 2002, 20:198-204.
149. Drummond M.W., Balabanov S., Holyoake T.L., Brummendorf T.H. Concise review: telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007, 25:1853-1861.
150. Hiyama K., Hirai Y., Kyoizumi S., et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995, 155:3711-3715.
151. Hahn W.C. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003, 21:2034-2043.
152. Adamson D.J., King D.J., Haites N.E. Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet 1992, 61:204-206.
153. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 2000, 60:610-617.
154. Hartmann U., Brümmendorf T.H., Balabanov S., Thiede C., Illme T., Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005, 90:307-316.
155. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002, 21:680-687.
156. Swiggers S.J.J., Kuijpers M.A., de Cort M.J.M., Beverloo H.B., Zijlmans J.M.J.M. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer 2006, 45:247-256.
157. Walne A.J., Marrone A., Dokal I. Dyskeratosis congenita: a disorder of defective telomere maintenance?. Int J Hematol 2005, 82:184-189.
158. Notaro R., Cimmino A., Tabarini D., Rotoli B., Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci U S A 1997, 94:13782-13785.
159. Wynn R.F., Cross M.A., Hatton C., et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998, 351:178-181.
160. Lee J., Kook H., Chung I., et al. Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 1999, 24:411-415.
161. Lahav M., Uziel O., Kestenbaum M., et al. Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation. Transplantation 2005, 80:969-976.
162. Rufer N., Brümmendorf T.H., Chapuis B., Helg C., Lansdorp P.M., Roosnek E. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood 2001, 97:575-577.